<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1352</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11479317</PubmedId>
            <Abstract>The fate of viral glycopeptides as cytotoxic T lymphocyte (CTL) epitopes is unclear. We have dissected the mechanisms of antigen presentation and CTL recognition of the peptide GP392-400 (WLVTNGSYL) from the lymphocytic choriomeningitis virus (LCMV) and compared them with those of the previously reported GP92-101 antigen (CSANNSHHYI). Both GP392-400 and GP92-101 bear a glycosylation motif, are naturally N-glycosylated in the mature viral glycoproteins, bind to major histocompatibility complex H-2D(b) molecules, and are immunogenic. However, post-translational modifications differentially affected GP92-101 and GP392-400. Upon N-glycosylation or de-N-glycosylation, a marked decrease in major histocompatibility complex binding was observed for GP392-400 but not for GP92-101. Further, under its N-glycosylated or de-N-glycosylated form, GP392-400 then lost its initial ability to generate a CTL response in mice, whereas GP92-101 was still immunogenic under the same conditions. The genetically encoded form of GP392-400, which on the basis of its immunogenicity could still be presented with H-2D(b) during the course of LCMV infection, does not in fact appear at the surface of LCMV-infected cells. Our results show that post-translational modifications of viral glycopeptides can have pleiotropic effects on their presentation to and recognition by CTL that contribute to either creation of neo-epitopes or destruction of potential epitopes.</Abstract>
            <ArticleYear>2001</ArticleYear>
            <ArticlePages>38255-60</ArticlePages>
            <ArticleTitle>Pleiotropic effects of post-translational modifications on the fate of viral glycopeptides as cytotoxic T cell epitopes.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Hudrisier</LastName>
                    <ForeName>D</ForeName>
                </Author>
                <Author>
                    <LastName>Riond</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Mazarguil</LastName>
                    <ForeName>H</ForeName>
                </Author>
                <Author>
                    <LastName>Gairin</LastName>
                    <ForeName>J E</ForeName>
                </Author>
            </Authors>
            <Affiliations>Institut de Pharmacologie et de Biologie Structurale, UMR5089 CNRS/Université Paul Sabatier, 205 route de Narbonne, 31400 Toulouse, France.</Affiliations>
            <ArticleChemicalList>Epitopes;Glycopeptides;Viral Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Epitopes(chemistry; metabolism); Glycopeptides(chemistry; metabolism); Lymphocytic choriomeningitis virus(metabolism); Mice; Mice, Inbred C57BL; Molecular Structure; Protein Conformation; Protein Processing, Post-Translational; T-Lymphocytes, Cytotoxic(immunology); Viral Proteins(chemistry; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>276</Volume>
                <Issue>41</Issue>
                <Title>The Journal of biological chemistry</Title>
                <Issn>1083-351X</Issn>
                <MedlineTa>J Biol Chem</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>GP92-101</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CSANNSHHYI</LinearSequence>
                        <StartingPosition>92</StartingPosition>
                        <EndingPosition>101</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 38255</LocationOfData>
                <EpitopeId>6972</EpitopeId>
                <ReferenceStartingPosition>92</ReferenceStartingPosition>
                <ReferenceEndingPosition>101</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The genetically encoded sequence for this subdominant epitope is N-glycosylated in the mature glycoprotein at N95 residue in the glycosylation motif NX(S/T).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2C</LocationOfData>
                        <TCellId>21700</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CSANNSHHYI</LinearSequence>
                                            <StartingPosition>92</StartingPosition>
                                            <EndingPosition>101</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>GP92-101</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50-100 μg mixed with 5 μg P30 T helper epitope from tetanus toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Lymph node cells</ResponderCellType>
                                <StimulatorCellType>RMA-lymphocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CSANNSHHYI</LinearSequence>
                                            <StartingPosition>92</StartingPosition>
                                            <EndingPosition>101</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>One week after immunization, lymph node cells were stimulated in vitro for 2 weeks.  CTL were restimulated weekly with irradiated C57BL/6 splenocytes and irradiated epitope-pulsed (1 mM) RMA cells in the presence of 30 UI/ml IL2.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>RMA-lymphocyte</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP92-101</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSANNSHHYI</LinearSequence>
                                        <StartingPosition>92</StartingPosition>
                                        <EndingPosition>101</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptide-pulsed target cells are efficiently lysed by CTLs from peptide immunized animals, as are target cells pulsed with both glycosylated and D95 (deaminated) post-translationally modified analogs, showing that these CTLs cross-react with the 3 possible forms of the epitope. The reactivity is higher for the D95 form than for the immunizing peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4C</LocationOfData>
                        <TCellId>21705</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CSANNSHHYI</LinearSequence>
                                            <StartingPosition>92</StartingPosition>
                                            <EndingPosition>101</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>GP92-101</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50-100 μg mixed with 5 μg P30 T helper epitope from tetanus toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Lymph node cells</ResponderCellType>
                                <StimulatorCellType>RMA-lymphocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CSANNSHHYI</LinearSequence>
                                            <StartingPosition>92</StartingPosition>
                                            <EndingPosition>101</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>One week after immunization, lymph node cells were stimulated in vitro for 2 weeks.  CTL were restimulated weekly with irradiated C57BL/6 splenocytes and irradiated epitope-pulsed (1 mM) RMA cells in the presence of 30 UI/ml IL2.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Virus infected target cells are efficiently lysed by CTLs from peptide immunized animals, demonstrating that this epitope is naturally presented at the surface of LCMV-infected cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 3B</LocationOfData>
                        <MhcBindingId>21704</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The level of stabilization of MHC molecules on RMA-S cells upon peptide incubation is similar for the genetically encoded, glycosylated and deaminated forms of this epitope. This is explained in a molecular modeling study by the fact that N96 serves as the anchoring residue for MHC binding, which is not affected by the glycosylation of N95.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>[GlcNac-N95]-GP92-101</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CSANNSHHYI</LinearSequence>
                        <ModifiedResidues>N4</ModifiedResidues>
                        <Modifications>Glycosylation</Modifications>
                        <StartingPosition>92</StartingPosition>
                        <EndingPosition>101</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 38255</LocationOfData>
                <EpitopeId>6971</EpitopeId>
                <ReferenceStartingPosition>92</ReferenceStartingPosition>
                <ReferenceEndingPosition>101</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The genetically encoded sequence for this subdominant epitope, is N-glycosylated in the mature glycoprotein at N95 residue in the glycosylation motif NX(S/T). An artificial peptide with GlcNac N-glycosylation is used to analyze the effect of glycosylation on MHC binding and CTL recognition.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2C</LocationOfData>
                        <TCellId>21712</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CSANNSHHYI</LinearSequence>
                                            <ModifiedResidues>N4</ModifiedResidues>
                                            <Modifications>Glycosylation</Modifications>
                                            <StartingPosition>92</StartingPosition>
                                            <EndingPosition>101</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>[GlcNac-N95]-GP92-101</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50-100 μg mixed with 5 μg P30 T helper epitope from tetanus toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>RMA-lymphocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CSANNSHHYI</LinearSequence>
                                            <ModifiedResidues>N4</ModifiedResidues>
                                            <Modifications>Glycosylation</Modifications>
                                            <StartingPosition>92</StartingPosition>
                                            <EndingPosition>101</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>The non-glycosylated, non-deamidated, form of this epitope was used as immunogen. One week after immunization, lymph node cells were stimulated in vitro for 2 weeks.  CTL were restimulated weekly with irradiated C57BL/6 splenocytes and irradiated epitope-pulsed (1 mM) RMA cells in the presence of 30 UI/ml IL2.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>RMA-lymphocyte</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>[GlcNac-N95]-GP92-101</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSANNSHHYI</LinearSequence>
                                        <ModifiedResidues>N4</ModifiedResidues>
                                        <Modifications>Glycosylation</Modifications>
                                        <StartingPosition>92</StartingPosition>
                                        <EndingPosition>101</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptide-pulsed target cells are lysed by CTLs from unglycosylated peptide immunized animals, but less efficiently than target cells pulsed with both the unglycosylated and D95 (deaminated) analogs, showing that these CTLs can cross-react with the 3 possible forms of the epitope, but the TCR recognition (since MHC binding is similar) is affected by glycosylation.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 3B</LocationOfData>
                        <MhcBindingId>21713</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The level of stabilization of MHC molecules on RMA-S cells upon peptide incubation is similar for the genetically encoded, glycosylated and deaminated forms of this epitope. This is explained in a molecular modeling study by the fact that N96 serves as the anchoring residue for MHC binding, which is not affected by the glycosylation of N95.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>[D95]-GP92-101</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CSANNSHHYI</LinearSequence>
                        <ModifiedResidues>N4</ModifiedResidues>
                        <Modifications>Deamidation|DEAM</Modifications>
                        <StartingPosition>92</StartingPosition>
                        <EndingPosition>101</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 38255</LocationOfData>
                <EpitopeId>6970</EpitopeId>
                <ReferenceStartingPosition>92</ReferenceStartingPosition>
                <ReferenceEndingPosition>101</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The genetically encoded sequence for this subdominant epitope, is N-glycosylated in the mature glycoprotein at N95 residue in the glycosylation motif NX(S/T). An artificial peptide, with the sequence CSADNSHHYI  as a N95D deaminated analog is used (as in vivo the de-N-glycosylation by cytoplasmic N-glycanases also deaminates residue N95 to a D residue in its place) to analyze the effect of deglycosylation/deamidation on MHC binding and CTL recognition.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2C</LocationOfData>
                        <TCellId>21715</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CSANNSHHYI</LinearSequence>
                                            <StartingPosition>92</StartingPosition>
                                            <EndingPosition>101</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>GP92-101</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50-100 μg mixed with 5 μg P30 T helper epitope from tetanus toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>RMA-lymphocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CSANNSHHYI</LinearSequence>
                                            <ModifiedResidues>N4</ModifiedResidues>
                                            <Modifications>Deamidation|DEAM</Modifications>
                                            <StartingPosition>92</StartingPosition>
                                            <EndingPosition>101</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>The non-glycosylated, non-deamidated, form of this eptiope was used as immunogen. One week after immunization, lymph node cells were stimulated in vitro for 2 weeks.  CTL were restimulated weekly with irradiated C57BL/6 splenocytes and irradiated epitope-pulsed (1 mM) RMA cells in the presence of 30 UI/ml IL2.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>RMA-lymphocyte</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>[D95]-GP92-101</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CSANNSHHYI</LinearSequence>
                                        <ModifiedResidues>N4</ModifiedResidues>
                                        <Modifications>Deamidation|DEAM</Modifications>
                                        <StartingPosition>92</StartingPosition>
                                        <EndingPosition>101</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptide-pulsed target cells are lysed by CTLs from unglycosylated-peptide immunized animals, even more efficiently than target cells pulsed with the immunogen. The glycosylated analog is also recognized, showing that these CTLs cross-react with the 3 possible forms of the epitope.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 3B</LocationOfData>
                        <MhcBindingId>21716</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The level of stabilization of MHC molecules on RMA-S cells upon peptide incubation is similar for the genetically encoded, glycosylated and deaminated forms of this epitope. This is explained in a molecular modeling study by the fact that N96 serves as the anchoring residue for MHC binding, which is not affected by the glycosylation of N95.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>GP392-400</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>WLVTNGSYL</LinearSequence>
                        <StartingPosition>392</StartingPosition>
                        <EndingPosition>400</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 38255</LocationOfData>
                <EpitopeId>72826</EpitopeId>
                <ReferenceStartingPosition>392</ReferenceStartingPosition>
                <ReferenceEndingPosition>400</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The genetically encoded sequence is N-glycosylated in the mature glycoprotein 2 at N396 residue in the glycosylation motif NX(S/T).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2A, and 2B</LocationOfData>
                        <TCellId>21723</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WLVTNGSYL</LinearSequence>
                                            <StartingPosition>392</StartingPosition>
                                            <EndingPosition>400</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>GP392-400</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50-100 μg mixed with 5 μg P30 T helper epitope from tetanus toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Lymph node cells</ResponderCellType>
                                <StimulatorCellType>RMA-lymphocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WLVTNGSYL</LinearSequence>
                                            <StartingPosition>392</StartingPosition>
                                            <EndingPosition>400</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>One week after immunization, lymph node cells were stimulated in vitro for several rounds.  CTL were restimulated weekly with irradiated C57BL/6 splenocytes and irradiated epitope-pulsed (1 mM) RMA cells in the presence of 30 UI/ml IL2.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>RMA-lymphocyte</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>GP392-400</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WLVTNGSYL</LinearSequence>
                                        <StartingPosition>392</StartingPosition>
                                        <EndingPosition>400</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptide-pulsed target cells (both RMA and MC57) are efficiently lysed by CTLs from peptide immunized animals, showing that this peptide is immunogenic in C57BL/6 mice. Target cells pulsed with both glycosylated and D95 (deaminated) post-translationally modified analogs are less efficiently lysed. Similar results are seen for a clone derived form the CTL line .</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4C</LocationOfData>
                        <TCellId>21724</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WLVTNGSYL</LinearSequence>
                                            <StartingPosition>392</StartingPosition>
                                            <EndingPosition>400</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>GP392-400</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50-100 μg mixed with 5 μg P30 T helper epitope from tetanus toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Lymph node cells</ResponderCellType>
                                <StimulatorCellType>RMA-lymphocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WLVTNGSYL</LinearSequence>
                                            <StartingPosition>392</StartingPosition>
                                            <EndingPosition>400</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>One week after immunization, lymph node cells were stimulated in vitro for several rounds.  CTL were restimulated weekly with irradiated C57BL/6 splenocytes and irradiated epitope-pulsed (1 mM) RMA cells in the presence of 30 UI/ml IL2.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Virus infected target cells are not lysed by CTLs from peptide immunized animals, demonstrating that this epitope is not naturally presented at the surface of LCMV-infected cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcLigandElution>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcLigandElutionId>21728</MhcLigandElutionId>
                        <HostOrganism>
                            <OrganismId>10090</OrganismId>
                        </HostOrganism>
                        <InVivoProcess>
                            <InVivoProcessType>No immunization</InVivoProcessType>
                        </InVivoProcess>
                        <InVitroAdministration>
                            <ProcessType>Antigen administered in vitro</ProcessType>
                            <ProcessedAntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </ProcessedAntigenObject>
                            <ProcessedAntigenEvidenceCode>Exact match to reference information</ProcessedAntigenEvidenceCode>
                        </InVitroAdministration>
                        <MhcLigand>
                            <MhcLigandReferenceName>GP392-400</MhcLigandReferenceName>
                            <MhcLigandObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WLVTNGSYL</LinearSequence>
                                        <StartingPosition>392</StartingPosition>
                                        <EndingPosition>400</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </MhcLigandObject>
                        </MhcLigand>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Inferred by motif or alleles present</MhcEvidenceCode>
                        </MhcAllele>
                        <AssayInformation>
                            <AssayTypeId>92</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The CTL line obtained after peptide immunization is not stimulated by the HPLC fractions of the material eluted from virus infected cells, further demonstrating that this epitope is not naturally presented upon infection.</AssayComments>
                        </AssayInformation>
                    </MhcLigandElution>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 3A</LocationOfData>
                        <MhcBindingId>21721</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The level of stabilization of MHC molecules on RMA-S cells upon peptide incubation is higher for the genetically encoded peptide than for the glycosylated and deaminated (D396) forms. This is explained in a molecular modeling study by the fact that N396 serves as the anchoring residue for MHC binding, which is then affected by the N-glycosylation or by its deamidation to a D residue (as a consequence of de-N-glycosylation).</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>[GlcNac-N396]-GP392-400</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>WLVTNGSYL</LinearSequence>
                        <ModifiedResidues>N5</ModifiedResidues>
                        <Modifications>Glycosylation</Modifications>
                        <StartingPosition>392</StartingPosition>
                        <EndingPosition>400</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 38255</LocationOfData>
                <EpitopeId>72825</EpitopeId>
                <ReferenceStartingPosition>392</ReferenceStartingPosition>
                <ReferenceEndingPosition>400</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The genetically encoded sequence is N-glycosylated in the mature glycoprotein 2 at N396 residue in the glycosylation motif NX(S/T). An artificial peptide with GlcNac N-glycosylation is used to analyze the effect of glycosylation on MHC binding and CTL recognition.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2A and 2B</LocationOfData>
                        <TCellId>21730</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WLVTNGSYL</LinearSequence>
                                            <ModifiedResidues>N5</ModifiedResidues>
                                            <Modifications>Glycosylation</Modifications>
                                            <StartingPosition>392</StartingPosition>
                                            <EndingPosition>400</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>[GlcNac-N396]-GP392-400</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50-100 μg mixed with 5 μg P30 T helper epitope from tetanus toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>RMA-lymphocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WLVTNGSYL</LinearSequence>
                                            <ModifiedResidues>N5</ModifiedResidues>
                                            <Modifications>Glycosylation</Modifications>
                                            <StartingPosition>392</StartingPosition>
                                            <EndingPosition>400</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>The non-glycosylated, non-deamidated, form of this epitope was used as immunogen. One week after immunization, lymph node cells were stimulated in vitro for several rounds.  CTL were restimulated weekly with irradiated C57BL/6 splenocytes and irradiated epitope-pulsed (1 mM) RMA cells in the presence of 30 UI/ml IL2.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>RMA-lymphocyte</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>[GlcNac-N396]-GP392-400</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WLVTNGSYL</LinearSequence>
                                        <ModifiedResidues>N5</ModifiedResidues>
                                        <Modifications>Glycosylation</Modifications>
                                        <StartingPosition>392</StartingPosition>
                                        <EndingPosition>400</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Glycosylated peptide-pulsed target cells are &gt;1000-fold less efficiently lysed than if pulsed with the nonglycosylated peptide by CTLs from nonglycosylated peptide-immunized animals. Similar results are seen with a clone derived from the CTL line.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcLigandElution>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcLigandElutionId>21733</MhcLigandElutionId>
                        <HostOrganism>
                            <OrganismId>10090</OrganismId>
                        </HostOrganism>
                        <InVivoProcess>
                            <InVivoProcessType>No immunization</InVivoProcessType>
                        </InVivoProcess>
                        <InVitroAdministration>
                            <ProcessType>Antigen administered in vitro</ProcessType>
                            <ProcessedAntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </ProcessedAntigenObject>
                            <ProcessedAntigenEvidenceCode>Exact match to reference information</ProcessedAntigenEvidenceCode>
                        </InVitroAdministration>
                        <MhcLigand>
                            <MhcLigandReferenceName>[GlcNac-N396]-GP392-400</MhcLigandReferenceName>
                            <MhcLigandObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WLVTNGSYL</LinearSequence>
                                        <ModifiedResidues>N5</ModifiedResidues>
                                        <Modifications>Glycosylation</Modifications>
                                        <StartingPosition>392</StartingPosition>
                                        <EndingPosition>400</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </MhcLigandObject>
                        </MhcLigand>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Inferred by motif or alleles present</MhcEvidenceCode>
                        </MhcAllele>
                        <AssayInformation>
                            <AssayTypeId>92</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The CTL line obtained after non-glycosylated peptide immunization is not stimulated by the HPLC fractions of the material eluted from virus infected cells, further demonstrating that this epitope is not naturally presented upon infection in neither its glycosylated or deaminated forms.</AssayComments>
                        </AssayInformation>
                    </MhcLigandElution>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 3A</LocationOfData>
                        <MhcBindingId>21729</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The level of stabilization of MHC molecules on RMA-S cells upon peptide incubation is strongly reduced (&gt;1000-fold) for the glycosylated form compared with the genetically encoded peptide. This is explained in a molecular modeling study by the fact that N396 serves as the anchoring residue for MHC binding, which is then affected by the glycosylation.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>[D396]-GP392-400</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>WLVTNGSYL</LinearSequence>
                        <ModifiedResidues>N5</ModifiedResidues>
                        <Modifications>Deamidation|DEAM</Modifications>
                        <StartingPosition>392</StartingPosition>
                        <EndingPosition>400</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11624</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 38255</LocationOfData>
                <EpitopeId>72824</EpitopeId>
                <ReferenceStartingPosition>392</ReferenceStartingPosition>
                <ReferenceEndingPosition>400</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The genetically encoded sequence is N-glycosylated in the mature glycoprotein 2 at N396 residue in the glycosylation motif NX(S/T). An artificial peptide, with the sequence WLVTDGSYL  as a N396D deaminated analog is used (as in vivo the de-N-glycosylation by cytoplasmic N-glycanases also deaminates residue N396 to a D residue in its place) to analyze the effect of deglycosylation/deamidation on MHC binding and CTL recognition.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2A and 2B</LocationOfData>
                        <TCellId>21735</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WLVTNGSYL</LinearSequence>
                                            <ModifiedResidues>N5</ModifiedResidues>
                                            <Modifications>Deamidation|DEAM</Modifications>
                                            <StartingPosition>392</StartingPosition>
                                            <EndingPosition>400</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>[D396]-GP392-400</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 50-100 μg mixed with 5 μg P30 T helper epitope from tetanus toxoid.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>RMA-lymphocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>WLVTNGSYL</LinearSequence>
                                            <ModifiedResidues>N5</ModifiedResidues>
                                            <Modifications>Deamidation|DEAM</Modifications>
                                            <StartingPosition>392</StartingPosition>
                                            <EndingPosition>400</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11624</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>The non-glycosylated, non-deamidated, form of this epitope was used as immunogen. One week after immunization, lymph node cells were stimulated in vitro for several rounds  CTL were restimulated weekly with irradiated C57BL/6 splenocytes and irradiated epitope-pulsed (1 mM) RMA cells in the presence of 30 UI/ml IL2.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>RMA-lymphocyte</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>[D396]-GP392-400</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WLVTNGSYL</LinearSequence>
                                        <ModifiedResidues>N5</ModifiedResidues>
                                        <Modifications>Deamidation|DEAM</Modifications>
                                        <StartingPosition>392</StartingPosition>
                                        <EndingPosition>400</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Deaminated peptide-pulsed target cells are ~1000-fold less efficiently lysed than if pulsed with the nonglycosylated peptide by CTLs from nonglycosylated peptide-immunized animals. Similar results are seen with a clone derived form the CTL line.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcLigandElution>
                        <LocationOfData>Figure 5</LocationOfData>
                        <MhcLigandElutionId>21736</MhcLigandElutionId>
                        <HostOrganism>
                            <OrganismId>10090</OrganismId>
                        </HostOrganism>
                        <InVivoProcess>
                            <InVivoProcessType>No immunization</InVivoProcessType>
                        </InVivoProcess>
                        <InVitroAdministration>
                            <ProcessType>Antigen administered in vitro</ProcessType>
                            <ProcessedAntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </ProcessedAntigenObject>
                            <ProcessedAntigenEvidenceCode>Exact match to reference information</ProcessedAntigenEvidenceCode>
                        </InVitroAdministration>
                        <MhcLigand>
                            <MhcLigandReferenceName>[D396]-GP392-400</MhcLigandReferenceName>
                            <MhcLigandObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WLVTNGSYL</LinearSequence>
                                        <ModifiedResidues>N5</ModifiedResidues>
                                        <Modifications>Deamidation|DEAM</Modifications>
                                        <StartingPosition>392</StartingPosition>
                                        <EndingPosition>400</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11624</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </MhcLigandObject>
                        </MhcLigand>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Inferred by motif or alleles present</MhcEvidenceCode>
                        </MhcAllele>
                        <AssayInformation>
                            <AssayTypeId>92</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The CTL line obtained after non-glycosylated peptide immunization is not stimulated by the HPLC fractions of the material eluted from virus infected cells, further demonstrating that this epitope is not naturally presented upon infection in neither its glycosylated or deaminated forms.</AssayComments>
                        </AssayInformation>
                    </MhcLigandElution>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 3A</LocationOfData>
                        <MhcBindingId>21734</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The level of stabilization of MHC molecules on RMA-S cells upon peptide incubation is measurable, but 100-fold lower for the deaminated form than for the genetically encoded peptide. This is explained in a molecular modeling study by the fact that N396 serves as the anchoring residue for MHC binding, which is then affected by the deglycosylation/deamidation to a D residue.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>172</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

